Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.

[1]  M. Socinski,et al.  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Hayes,et al.  Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  E. Yorke,et al.  High-Dose Radiotherapy for the Treatment of Inoperable Non–Small Cell Lung Cancer , 2007, Cancer journal.

[4]  Joe Y. Chang,et al.  The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Patrice Jalade,et al.  Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[7]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[8]  Suresh Senan,et al.  A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer , 2006, Radiation oncology.

[9]  G. Silvestri,et al.  Conformal High Dose External Radiation Therapy, 80.5 Gy, Alone for Medically Inoperable Non-small Cell Lung Cancer: A Retrospective Analysis , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  S. Hancock,et al.  Diastolic dysfunction after mediastinal irradiation. , 2005, American heart journal.

[11]  Lawrence B Marks,et al.  The incidence and functional consequences of RT-associated cardiac perfusion defects. , 2005, International journal of radiation oncology, biology, physics.

[12]  S. Motl.  Bevacizumab in combination chemotherapy for colorectal and other cancers. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[14]  M. Socinski,et al.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Socinski,et al.  Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium , 2004 .

[16]  Kai-Liang Wu,et al.  Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. , 2003, International journal of radiation oncology, biology, physics.

[17]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[18]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[19]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[20]  H. Bartelink,et al.  LATE EFFECTS TOXICITY SCORING : THE SOMA SCALE , 1995 .

[21]  C. Perez,et al.  Impact of tumor control on survival in carcinoma of the lung treated with irradiation. , 1986, International journal of radiation oncology, biology, physics.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  N. Girard,et al.  [Chemoradiation for locally advanced non-small cell lung cancer]. , 2007, Cancer Radiothérapie.

[24]  F. Mornex,et al.  Chimioradiothérapie exclusive des cancers bronchiques non à petites cellules localement évolués , 2007 .

[25]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[27]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[28]  D. Karnofsky.  The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[29]  Colin M. MacLeod,et al.  Evaluation of chemotherapeutic agents , 1949 .